Abstract:Abstract The TGF-β signaling pathway governs key cellular processes under physiologic conditions and is deregulated in many pathologies, including cancer. TGF-β is a multifunctional cytokine that acts in a cell- and context-dependent manner as a tumor promoter or tumor suppressor. As a tumor promoter, the TGF-β pathway enhances cell proliferation, migratory invasion, metastatic spread within the tumor microenvironment and suppresses immunosurveillance. Collectively, the pleiotropic nature of TGF-β signaling contributes to drug resistance, tumor escape and undermines clinical response to therapy. Based upon a wealth of preclinical studies, the TGF-β pathway has been pharmacologically targeted using small molecule inhibitors, TGF-β-directed chimeric monoclonal antibodies, ligand traps, antisense oligonucleotides and vaccines that have been now evaluated in clinical trials. Here, we have assessed the safety and efficacy of TGF-β pathway antagonists from multiple drug classes that have been evaluated in completed and ongoing trials. We highlight Vactosertib, a highly potent small molecule TGF-β type 1 receptor kinase inhibitor that is well-tolerated with an acceptable safety profile that has shown efficacy against multiple types of cancer. The TGF-β ligand traps Bintrafusp alfa (a bifunctional conjugate that binds TGF-β and PD-L1), AVID200 (a computationally designed trap of TGF-β receptor ectodomains fused to an Fc domain) and Luspatercept (a recombinant fusion that links the activin receptor IIb to IgG) offer new ways to fight difficult-to-treat cancers. While TGF-β pathway antagonists are rapidly emerging as highly promising, safe and effective anticancer agents, significant challenges remain. Minimizing the unintentional inhibition of tumor-suppressing activity and inflammatory effects with the desired restraint on tumor-promoting activities has impeded the clinical development of TGF-β pathway antagonists. A better understanding of the mechanistic details of the TGF-β pathway should lead to more effective TGF-β antagonists and uncover biomarkers that better stratify patient selection, improve patient responses and further the clinical development of TGF-β antagonists.

Targeting the TGF-β signaling pathway: an updated patent review (2021–present)

[Crosstalk Between Canonical TGF-β/Smad and Wnt/β-catenin Signaling Pathway].

TGF-β signaling in health, disease, and therapeutics

Research progress on drugs targeting the TGF-β signaling pathway in fibrotic diseases

TGF-beta signal transduction: biology, function and therapy for diseases

Recent progress in TGF-β inhibitors for cancer therapy

Targeting TGFβ signal transduction for cancer therapy

The Role of TGF-β Signaling Pathways in Cancer and Its Potential as a Therapeutic Target

Novel therapies emerging in oncology to target the TGF-β pathway

Targeting TGF-β signal transduction for fibrosis and cancer therapy

Targeting transforming growth factor‐β signalling for cancer prevention and intervention: Recent advances in developing small molecules of natural origin

Transforming growth factor-β receptors: versatile mechanisms of ligand activation

TGF-β in Hepatic Stellate Cell Activation and Liver Fibrogenesis—Updated 2019

A FGFR1 inhibitor patent review: progress since 2010

Regulation of TGF-β Receptor Activity

Novel inhibitors of the STAT3 signaling pathway: an updated patent review (2014-present)

TGF-β: A novel predictor and target for anti-PD-1/PD-L1 therapy

Targeting TGF-β Signaling in Cancer.

Targeting the transforming growth factor-β signaling pathway in human cancer

An updated patent review of Akt inhibitors (2016-present)

An updated patent review of AKT inhibitors (2020 - present)